Abstract

The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 14/74 - Major histocompatibility complex [MHC]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/82 - Translation products from oncogenes

Abstract

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/735 - Fc receptors
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The invention provides compositions and methods for modulating expression of SUV39H1 using inhibitory or activating polynucleotides based on the sequence of a long noncoding RNA or of a short hairpin RNA (shRNA).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/32 - T-cell receptors [TCR]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to the use of KMT inhibitors and in particular of Suv39h1 inhibitors to increase immune response, and in particular immune cell mediated response, notably elicited by a vaccine or immunogenic composition.

IPC Classes  ?

• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/74 - Major histocompatibility complex [MHC]
• C12N 5/078 - Cells from blood or from the immune system

Abstract

The invention provides immune cells defective for SUV39H1 with enhanced properties

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention provides compositions and methods for modulating expression of SUV39H1 using inhibitory or activating polynucleotides based on the sequence of a long noncoding RNA or of a short hairpin RNA (shRNA).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The disclosure also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/12 - Mumps virusMeasles virus
• C07K 1/00 - General processes for the preparation of peptides

Abstract

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans

Abstract

The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07K 14/725 - T-cell receptors

Goods & Services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical preparations; biological and pharmaceutical preparations; biological and pharmaceutical preparations for cancer and tumor treatment using immunotherapy; therapeutic preparations namely antigens, antibodies, T cells; material, preparations, reagents for products for medical use; antigens, antibodies, cells for therapeutic use. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacture of therapeutic solutions namely antigens, antibodies, T cells. Scientific research services for medical purposes; antigen identification, screening and development services; scientific and technological services; scientific laboratory services; providing scientific and medical information with regard to immunotherapy; providing services for identifying, analyzng, authenticating, purifying and developing biological material from a genomic platform; epigenetic antigen screening and identification services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses. Providing information in the field of manufacturing pharmaceuticals; providing medical information with regard to immunotherapy.

Goods & Services

biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for the treatment of cancer and tumors; biological and pharmaceutical preparations for cancer and tumor treatment using immunotherapy; therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical products for medical use for the treatment of cancer and tumors; diagnostic preparations for medical purposes, namely, antigens, antibodies, cells for therapeutic use Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; custom manufacture of therapeutic solutions, namely, antigens, antibodies, T cells providing medical information with regard to immunotherapy Scientific research services for medical purposes; scientific research and product development, namely, antigen identification, screening and development services; scientific and technological research services in the field of oncology and immunotherapy; scientific laboratory services; providing scientific and medical research information with regard to immunotherapy; scientific research and development, namely, providing services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform; scientific research, namely, epigenetic antigen screening and identification services for therapeutic research purposes; medical research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; providing medical and scientific research information, namely, designing algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform for use in forecasting the characteristics of antigens and immunological responses through the use of algorithms

Goods & Services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical products; biological and pharmaceutical preparations; biological and pharmaceutical preparations for treating cancer and tumors using immunotherapy; preparing therapeutic solutions, namely, antigen, antibodies, T-cells; biological materials, preparations, reagents for medical products; antigens, antibodies, cells for therapeutic use. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacturing antigens, antibodies, T-cells; providing information in the field of manufacturing pharmaceuticals. Scientific research services for medical purposes; identifying, screening and developing antigens; scientific and technological services; scientific laboratory services; providing scientific and medical information on immunotherapy; providing services for identifying, analyzng, authenticating, purifying and developing biological material from a genomic platform; epigenetic antigen screening and identification services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses. Providing medical information relating to immunotherapy.

Goods & Services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical products; biological and pharmaceutical preparations; biological and pharmaceutical preparations for the treatment of cancer and tumors using immunotherapy; preparing therapeutic solutions, namely, antigen, antibodies, T-cells; biological materials, preparations, reagents for products for medical use; antigens, antibodies, cells for therapeutic use. Medical apparatus and instruments; apparatus and instruments for carrying out tests and diagnostics for medical use; apparatus and instruments for identifying, screening, analyzing and developing antigens for medical use; medical apparatus for reading of analytical tests. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacturing antigens, antibodies, T-cells; providing information in the field of manufacturing pharmaceuticals. Scientific research services for medical purposes; services for identifying, screening and developing antigens; scientific and technological services; scientific laboratory services; providing scientific and medical information with regard to immunotherapy; providing services for the identification, analysis, authentication, purification and development of biological material from a genomic platform; epigenetic antigen identification and screening services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; services of computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; services of a computer software platform enabling the use of algorithms for predicting the characteristics of antigens and immunological responses. Providing medical information with regard to immunotherapy.

Goods & Services

Biological and chemical preparations for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions Pharmaceutical products for use in the fields of oncology and immunotherapy; biological and pharmaceutical preparations for treatment of cancer and tumors; biological and pharmaceutical preparations for treating cancer and tumors using immunotherapy; preparing therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical for products for medical use in the treatment of cancer and tumors; pharmaceutical antigens, antibodies, and cells for therapeutic use Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; custom manufacturing of antigens, antibodies, T-cells; Providing medical information relating to immunotherapy; information, advice and consulting services related to the field of pharmaceutical products manufacturing Scientific research services, namely medical research; scientific research and product development, namely, identifying, screening and developing antigens; scientific and technological services, namely, scientific research, analysis and testing in the field of oncology and immunotherapy; scientific laboratory services; providing scientific and medical research information on immunotherapy; providing scientific research services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform; scientific analysis, namely, epigenetic antigen screening and identification services for therapeutic research purposes; scientific research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; providing temporary use of online non-downloadable computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; providing temporary use of online non-downloadable computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses Providing medical information relating to immunotherapy

Goods & Services

Biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions Pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for treatment of cancer and tumors; biological and pharmaceutical preparations for the treatment of cancer and tumors using immunotherapy; therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical for products for medical use in the treatment of cancer and tumors; antigens, antibodies, cells for therapeutic use apparatus and instruments for carrying out tests and diagnostics for medical use, namely, medical imaging, biopsies, genetic and molecular analysis ; medical apparatus and instruments for identifying, screening, and analyzing antigens for medical use; medical apparatus for reading of analytical tests, namely molecular, blood and genetic testing Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; Custom manufacturing of antigens, antibodies, T-cells; Providing manufacturing information in the field of pharmaceuticals Scientific research services for medical purposes, namely, medical research; Scientific research and development services for identifying, screening and developing antigens; scientific and technological services, namely, scientific research, analysis and testing in the field of oncology and immunotherapy; scientific laboratory services; providing scientific information with regard to immunotherapy; Scientific research and development services, namely, providing services for the identification, analysis, authentication, purification and development of biological material from a genomic platform; Scientific research, namely, epigenetic antigen identification and screening services for therapeutic research purposes; Scientific research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; Scientific and medical research services, namely, designing algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform featuring algorithms for predicting the characteristics of antigens and immunological responses Providing medical information with regard to immunotherapy

Abstract

The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: - a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and - a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Goods & Services

Pharmaceutical products, medical preparations; chemical-pharmaceutical preparations; chemical preparations for pharmaceutical use; chemical preparations for medical use; diagnostic preparations for medical use; medicines for human medicine; remedies for human medicine; pharmaceutical preparations; biological preparations for medical use; capsules for medicines. Medical apparatus and instruments; receptacles for applying medicines; containers especially made for medical waste; diagnostic apparatus for medical use. Medical services; medical analysis services relating to patient treatment (such as X-rays and blood tests); medical analysis services provided by medical laboratories for diagnostic and therapeutic purposes; medical assistance; advice relating to health; health services; medical equipment rental.

Goods & Services

(1) Produits pharmaceutiques pour le traitement de tumeurs et de cancers; préparations médicinales à utiliser en oncologie et en l'immunothérapie; préparations biologiques et pharmaceutiques pour traitement par immunothérapie; préparations biologiques et pharmaceutiques pour le traitement de cancer et tumeurs; Préparation de solutions thérapeutiques pour le traitement de maladies infectieuses, auto-immunes et des tumeurs malignes, à savoir antigènes, anticorps, cellules immunitaires ou progénitrices; préparations pour le diagnostic dans les domaines de l'oncologie et de l'immunothérapie. (2) Récipients spéciaux pour déchets médicaux. (1) Services d'analyses médicales pour le diagnostic et le traitement dans les domaines de l'oncologie et de l'immunothérapie; services d'analyses médicales fournis par des laboratoires médicaux à des fins diagnostiques et thérapeutiques; conseils en matière d'immunothérapie et de services d'immunothérapie; location d'équipements médicaux.

Goods & Services

Pharmaceutical products for the treatment of cancerous tumors and auto-immune or infectious diseases; chemical preparations for pharmaceutical use for the treatment of cancerous tumors and auto-immune or infectious diseases; chemical preparations for medical use for the treatment of cancerous tumors and auto-immune or infectious diseases; diagnostic preparations for medical use for the treatment of cancerous tumors and auto-immune or infectious diseases Medical services